American Thyroid Association (ATA) to Honor Bryan Haugen, MD, with Paul Starr Award and Lectureship at 82nd Annual Meeting
Source Newsroom: American Thyroid Association
Newswise — Falls Church, Virginia. Sept. 19, 2012 – The American Thyroid Association (ATA) today announced it will honor Bryan R. Haugen, MD, of the University of Colorado, with the 2012 Paul Starr Award on Sept. 22 at the 82nd ATA Annual Meeting, in Québec City, Québec, Canada. The Paul Starr Award recognizes an outstanding contribution of an ATA member to clinical thyroidology.
Upon acceptance of the Award, Dr. Haugen will deliver the Paul Starr Award Lecture entitled “The Accidental Clinician-Scientist.” Dr. Haugen will also receive an honorarium supported by Dr. Boris Catz.
“Dr. Haugen’s research has yielded unprecedented insights into the field of clinical thyroidology. His impressive body of work include important insights into our understanding of the pathogenesis of thyroid cancer, and clinical studies that have significantly impacted how we diagnose, treat, and manage the disease,” said ATA President James A. Fagin, MD, of Memorial Sloan-Kettering Cancer Center.
Dr. Haugen is Professor of Medicine and Pathology at the University of Colorado Denver. He is also Chief of the Division of Endocrinology, Metabolism & Diabetes and Director of the Thyroid Tumor Program and holds the Mary Rossick Kern and Jerome H. Kern Chair in Endocrine Neoplasms Research. Over the past year he has been principal investigator of three National Institutes of Health (NIH) grants. He has published 63 articles in peer-reviewed literature, predominantly in the field of pathophysiology, diagnosis, and management of thyroid cancer and nodules.
Dr. Haugen’s career has centered around basic and clinical research into the novel diagnosis and management of thyroid cancer and nodules. He has been on the forefront of the use of new proteomic approaches to molecular markers in thyroid neoplasms and has avidly pursued molecular studies regarding the pathophysiology of thyroid tumors and new molecular targets for therapy, including nuclear hormone receptors (RXR, TR, PPAR, NFkB) and kinase signaling pathways
Dr. Haugen is an active member of the National Thyroid Tumor Registry and has been a co-author on its numerous publications. He is chair of the ATA Nodules and Thyroid Cancer Management Guidelines Task Force and previously served on the writing group for the 2009 Revised ATA Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Dr. Haugen is president-elect of the ATA and has served on many ATA committees during his years of membership since 1994.
About the ATA Annual Meeting
The 82nd Annual Meeting of the American Thyroid Association will be held Sept. 19-23, in Québec City, Québec, Canada. This four-day creative and innovative scientific program, chaired by Elizabeth Pearce, MD, Boston Medical Center, and Douglas Forrest, PhD, National Institute of Diabetes and Digestive and Kidney Diseases, carefully balances clinical and basic science sessions on the latest advances in thyroidology. The ATA meeting is designed to offer continuing education for endocrinologists, internists, surgeons, basic scientists, nuclear medicine scientists, pathologists, endocrine fellows and nurses, physician assistants and other health care professionals. Visit www.thyroid.org for more information.
About the ATA
The American Thyroid Association (ATA) is the leading worldwide organization dedicated to the advancement, understanding, prevention, diagnosis and treatment of thyroid disorders and thyroid cancer. ATA is an international individual membership organization with over 1,600 members from 43 countries around the world. Celebrating its 89th anniversary, ATA delivers its mission through several key endeavors: the publication of highly regarded monthly journals, THYROID, Clinical Thyroidology and Clinical Thyroidology for Patients; annual scientific meetings; biennial clinical and research symposia; research grant programs for young investigators, support of online professional, public and patient educational programs through www.thyroid.org; and the development of guidelines for clinical management of thyroid disease. Visit www.thyroid.org for more information.
# # #